secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001140361-22-028807
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO reports Q2 2022 net loss of $28.1M, cash runway into Q1 2024
--------------------------------------------------------------------

- Net loss of $28.1M in Q2 2022 vs $31.4M in Q2 2021; R&D expenses $18.9M, down from $22.5M.
- Cash and equivalents $132.4M as of June 30, 2022, down from $189.6M at Dec 31, 2021; runway into Q1 2024.
- All five patients in Phase 1/2 cystinosis trial remain off oral cysteamine post gene therapy.
- FDA Orphan Drug Designation granted for AVR-RD-05 in Hunter syndrome; CTA authorization expected 2H 2022.
- Plan to engage with regulators on cystinosis and Gaucher type 3 clinical strategies in 2H 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000114036122028807/0001140361-22-028807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000114036122028807/brhc10040479_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-028807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer